SCHOOL platform: Biophysical principles

SCHOOL platform for receptor signaling

SCHOOL concept: Learning from viruses

SCHOOL approach to sepsis, lung cancer, breast and pancreatic cancer, autoimmune diseases and others


Multichain Immune Recognition Receptor Signaling From Spatiotemporal Organizaiton to Human Disease


  • SignaBlok has been highlighted by Mass High Tech as a top company to watch
    Read more
  • SignaBlok targets $2.5M funding to treat lung, breast cancer
    Read more
  • SignaBlok aims to condense virus evolution, discover new drug solutions
    Read more
  • UMass research focuses on anti-clotting platform
    Read more





Year est.


New Therapeutic Approach to Sepsis: Inhibition of TREM-1 Signaling with Transmembrane Peptide Variants

Contract agreement



Multifunctional nanoformulations for diagnostic imaging of atherosderosis

Phase I SBIR grant



Development of novel targeted
agents in lung cancer

Phase I SBIR grant



Novel treatment development
for cancer cachexia

Collaboration agreement


1 The Defense Advanced Research Projects Agency (DARPA) is a component of the United States Department of Defense, focused on sponsoring revolutionary, high-payoff research bridging the gap between fundamental discoveries and their military and civilian use.

2 The National Heart, Lung, and Blood Institute (NHLBI) is a component of the National Institutes of Health (NIH), focused on providing global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases.

3 The National Cancer Institute (NCI) is a component of the National Institutes of Health (NIH) and the Federal Government's principal agency for cancer research and training.

4 The University of Texas Southwestern Medical Center (UTSMC) is one of the leading medical schools and biomedical research institutions in the United States.

We are seeking partnerships and collaborations with granting agencies, disease foundations, and academia through SBIR/STTR projects or other mechanisms, as well as with larger and more established biotech and pharma companies to take products through the animal studies and clinical trials process and/or to license our products.


Collaborative R&D, secure strategic alliances, joint ventures, partnerships, licensing deals, etc.


GPVI inhibitors

TCR inhibitors

TREM-1 inhibitors




Thrombotic disorders

Rheumatoid arthritis, dermatitis, scleroderma

Non-small cell lung cancer, breast cancer, sepsis, hemorrhagic shock

Breast and lung cancer, infectious diseases, sepsis, atherosclerosis

Breast and lung cancer, atherosclerosis


Systemic and stent coatings

Systemic and topical

Systemic and topical

Systemic nanoparticulate therapeutics and imaging agents

Image-guided therapy


* GPVI, glycoprotein VI (the major collagen receptor on platelets); TCR, T cell receptor; TREM-1, triggering receptor expressed on myeloid cells-1

- Understanding Nature. Improving Life.

Fact Sheet

Press Releases

  • SignaBlok Awarded NIH Grant to Test New Therapy for Rheumatoid Arthritis
    Read more
  • SignaBlok Wins NIH Grant to Advance New Technology for Atherosclerosis Imaging
    Read more
  • SignaBlok Achieves Key In Vivo Proof of Concept for Treatment of Cancer and Sepsis
    Read more
  • SignaBlok Announces Notice of Patent Allowance on TREM-1 Peptide Therapeutics for Sepsis and Cancer
    Read more
  • SignaBlok Receives NCI Grant to Test New Approach to Lung Cancer Treatment
    Read more
  • SignaBlok Receives NIH Grant to Develop Targeted Imaging of Atherosclerosis
    Read more
  • SignaBlok Awarded DARPA Contract to Support New Technology to Combat Sepsis
    Read more